| 
| 
| 
|
Bin Wang CSO Advaccine
| David Weiner EVP The Wistar Institute | George Siber President Siber Biotechnologies | Heinrich Hass Former VP, BioNtech |
|
|
|
|
 |  |  |  |
Dexiang Chen Chairman&GM
Maxvax
| Chunlin Xin VP Cansino Biologics | Alain Bouckenooghe CSO Hilleman Laboratories | Kiat Ruxrungtham Director,Chula VRC CHULALONGKORN UNIVERSITY |
 |  |  |  |
Li Shi Board Chairman Immune-Path Bio
| Yuan Yuan China Country Rep. PATH | PetroTerblanche CEO Afrigen Biologics | Sean Du Head, External R&D,APAC Sanofi Pasteur |
|
|
|
|
 |  | 
| 
|
Shaowei Li Professor Xiamen University | Yuanqing Liu CSO China Immorna | Anna Du Senior Program Officer
Bill & Melinda Gates Foundation | Joon Haeng Rhee Professor Chonnam National University Medical School |
|
|
|
|
| 
| 
| 
|
Linqi Zhang Professor Tsinghua University
| Dianna Boraschi Distinguished Professor Shenzhen Institute ofAdvanced Technology
| Simon Graham Professor The Pirbright Institute
| Emanuele Montomoli Full Prof. of Public Health University of Siena/CSO, VisMederi
|
|
|
|
|
Michel De Wilde Former SVP, R&D, Sanofi Pasteur; Owner, MDW Consultant | Raman Rao, CEO, Hilleman Laboratories | Meng Li
Head of Board Office, Director of International Cooperation, China National Biotec Group | Xiaofeng Liang VP, Chinese Preventive Medicine Association Professor, Jinan University
|
|
|
|
|
Ruben Rizzi SVP of Global Regulatory Affairs, BioNTech | Huichen Guo
Professor Lanzhou Veterinary Research Institute |
Yuelong Shu Director General Institute of Pathogen Biology, CAMS & PUMC, China
| George Fu Gao
Former Director, China CDC Professor, Chinese Academy of Sciences |
